When was Tempus founded?

Tempus was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Where is Tempus located?

Tempus is headquartered in Chicago, United States. It is registered at El Segundo, California.

Who is the current CEO of Tempus?

Eric Lefkofsky of Tempus. They have also founded 7 companies and are angel investors in 4 startups, including Olivia health and Flashtalking.

How many employees does Tempus have?

As of Apr 30, 2026, the latest employee count at Tempus is 3023.

Is Tempus a funded company?

Tempus is a funded company, having raised a total of $1.05B across 8 funding rounds to date. The company's 1st funding round was a $70M Series C round, raised on Sep 22, 2017.

When was the latest funding round of Tempus?

Tempus' latest funding was a Conventional Debt round on Oct 20, 2022, with participation from 0 investor.

Is Tempus a Artificial Intelligence company?

The primary sectors of Tempus are Artificial Intelligence, Healthcare IT and Life Sciences Tech.

Where does Tempus rank among its competitors?

Tempus ranks 4th amongst 323 active competitors, of which 60 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Verily, which secured $300M in Mar, 2026.

Who are the top competitors of Tempus?

Tempus' top competitors include Medidata, IQVIA and Verily. Among them, Verily secured the most recent funding round in March, 2026.

Tempus - 2026 Company Profile, Team, Funding & Competitors

Tempus is a public company based in Chicago (United States), founded in 2015 by Eric Lefkofsky. It operates as a Developer of genomic sequencing and algorithmic diagnostic tools for medicine. Tempus has raised $1.05B in funding from investors like New Enterprise Associates, T. Rowe Price and Revolution. The company has 323 active competitors, including 60 funded and 43 that have exited. Its top competitors include companies like Medidata, IQVIA and Verily.

Sectors and market segments that Tempus operate in

Tempus serves in the Native AI, HealthTech, Life Sciences market segments.The primary business model of Tempus are:

Company Details

Developer of genomic sequencing and algorithmic diagnostic tools for medicine. The organization provides molecular profiling and data analysis services to assist in clinical decision-making. The technology platform integrates clinical data with genomic sequencing to identify therapeutic options and match patients to clinical trials. It also offerings include digital pathology, radiology analysis, and software for electronic health record integration. The tools support research and development in oncology, neurology, psychiatry, and cardiology by identifying biomarkers and predicting treatment responses. The platform facilitates the analysis of multimodal data to assist in identifying gaps in care and enhancing patient outcomes through precision medicine.

Website: www.tempus.com/
Social
Email ID: *****@tempus.com
Registered Address: El Segundo, California

Key Metrics

Founded Year

2015

Location

Chicago, United States

Stage

Public

Total Funding

$1.05B in 8 rounds

Latest Funding Round

Conventional Debt, Oct 20, 2022, Undisclosed

Investors

New Enterprise Associates & 11 more

Ranked

4^th among 323 active competitors

Employee Count

3,023 as on Apr 30, 2026

Investment & Acquisitions

PAIGE & 5 more

Similar Companies

Medidata & 2674 more

Exit Details

Public

View Tempus' full profile

Tempus is associated with 5 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Tempus Ai, Inc. CIN: 1717115 , United States, Active		$1.27B (As on Dec 31, 2025)	-	-
Tempus Ai, Inc. CIN: 20181095311 , United States, Active	Jan 31, 2018	-	-	-
TEMPUS INC CIN: 391923550 , United States, Active	Dec 31, 2014	-	32 (As on Dec 31, 2024)	-
TEMPUS, LLC CIN: 954834686 , United States, Active	Dec 26, 999	-	772 (As on Dec 31, 2022)	-
TEMPUS CIN: 40203017317 , Latvia, Active	Sep 05, 2016	$1.07M (As on Dec 31, 2024)	3 (As on Dec 31, 2023)	-

Tempus got listed on Jun 14, 2024.

Click here to take a look at Tempus's IPO in detail

Tempus has raised a total funding of $1.05B over 8 rounds. Its first funding round was on Sep 22, 2017. Tempus has 12 institutional investors.

Here is the list of recent funding rounds of Tempus:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 20, 2022	Undisclosed	Conventional Debt	-	-	-	-
Oct 20, 2022	Undisclosed	Series G	-	-	-	-
Dec 10, 2020	$200M	Series G	$8.1B	-	Google	Novo Holdings, Baillie Gifford, Franklin Templeton Investments, T. Rowe Price

Access funding benchmarks and valuations. Sign up today!

View details of Tempus's funding rounds and investors

The founders of Tempus is Eric Lefkofsky. Eric Lefkofsky is the CEO of Tempus.

Here are the details of Tempus' key team members:

Eric Lefkofsky: Founder & CEO of Tempus and founder of 7 other companies, including Olivia health, Flashtalking and Flashtalking Production. They are also an angel investor in 4 startups.
Contact Info: 4 email addresses

View details of Tempus's Founder profiles and Board Members

Tempus' employee count trend

Tempus has 3,023 employees as of Apr 26. Here is Tempus's employee count trend over the years:

Uncover Tempus' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Tempus include Medidata, IQVIA and Verily. Here is the list of Top 10 competitors of Tempus, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Medidata 1999, New York City (United States), Acquired	AI-based clinical trial management software for researchers	$41.5M	Insight Partners, TFS & 11 others	86/100
2nd	IQVIA 1982, Durham (United States), Public	Provider of clinical research and commercialization solutions for healthcare	$1.74M	Leonard Green and Partners, Fisher Lynch Capital ... & 10 others	80/100
3rd	Verily 2015, Dallas (United States), Series D	Developer of precision health platforms and solutions using artificial intelligence	$2.8B	Silver Lake, Temasek & 9 others	79/100
4th	Tempus 2015, Chicago (United States), Public	Developer of genomic sequencing and algorithmic diagnostic tools for medicine	$1.05B	Baillie Gifford, Lightbank & 10 others	74/100
5th	Signant Health 2000, Plymouth Meeting (United States), Acquired	Provider of a software solution for clinical trial management	$3.4M	Harvest Partners, 3i Group & 3 others	72/100
6th	Science 37 2014, Los Angeles (United States), Acquired	Provider of a suite solution for clinical trials for researchers	$106M	Redmile Group, Lux Capital & 12 others	70/100
7th	Viz.ai 2016, San Francisco (United States), Series D	Developer of an AI-powered platform for care coordination and disease detection	$252M	Insight Partners, Tiger Global Management ... & 16 others	69/100
8th	TriNetX 2013, Cambridge (United States), Acquired	Provider of clinical trial management software for researchers and professionals	$102M	Merck Global Health Innovation Fund, MPM Capital ... & 5 others	66/100
9th	BrightInsight 2017, San Jose (United States), Series C	Provider of digital health solutions for clinical trials	$179M	Insight Partners, General Catalyst & 8 others	64/100
10th	Atrys 2007, Barcelona (Spain), Public	Provider of diagnostic and therapeutic services catering to cancer	-	Inveready, Deutsche Bank & 4 others	64/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Tempus's competitors? Click here to see the top ones

Tempus has not made any investments yet. Tempus has made 6 acquisitions.

Here is the list of latest three $acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Aug 22, 2025	Acquisition	PAIGE	2018	New York City (United States)
Mar 11, 2025	Acquisition	Deep 6 AI	2013	Pasadena (United States)
Nov 05, 2024	Acquisition	Ambry Genetics	1999	Aliso Viejo (United States)